Results 41 to 50 of about 34,423 (243)

CA19-9 elevation in ovarian mature cystic teratoma: Discrimination from ovarian cancer – CA19-9 level in teratoma [PDF]

Medical Science Monitor, 2013
We aimed to identify clinical characteristics of ovarian mature cystic teratoma (MCT) in association with CA19-9 elevation, and to determine if CA19-9 is a useful marker in discrimination of MCT from ovarian cancer (OC).Medical records of 322 women with pathologically-confirmed MCT or OC (stage 1 or 2) were reviewed retrospectively.
Cho, Hye-yon, Kim, Kidong, Jeon, Yong-Tark, Kim, Yong-Beom, No, Jae Hong   +4 more
openaire   +2 more sources

Optimal value of CA19-9 determined by KRAS-mutated circulating tumor DNA contributes to the prediction of prognosis in pancreatic cancer patients

Scientific Reports, 2021
Despite the acceptance of carbohydrate antigen 19-9 (CA19-9) as a valuable predictor for the prognosis of pancreatic ductal adenocarcinoma (PDAC), its cutoff value remains controversial.
Fumiaki Watanabe, Koichi Suzuki, Sawako Tamaki, Iku Abe, Yuhei Endo, Yuji Takayama, Hideki Ishikawa, Nao Kakizawa, Masaaki Saito, Kazushige Futsuhara, Hiroshi Noda, Fumio Konishi, Toshiki Rikiyama   +12 more
doaj   +1 more source

Proposed carbohydrate antigen 19-9 (CA19-9) cut-off values for the detection of pancreatic cancer in patients with poorly controlled diabetes: a real-world study

Endocrine Journal, 2023
CA19-9 is a tumor marker for pancreatic cancer (PC), and the nondiabetic cut-off level is 37 U/mL. CA19-9 levels are said to rise in patients with tumors like PC and intraductal papillary mucinous neoplasm (IPMN). CA19-9 levels have also been shown to be
Taku Yamada, Taichi Minami, Masayo Yamada, Yasuo Terauchi   +3 more
doaj   +1 more source

A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial. [PDF]

, 2017
Lessons learnedThe addition of the heat shock protein 27 (Hsp27)-targeting antisense oligonucleotide, apatorsen, to a standard first-line chemotherapy regimen did not result in improved survival in unselected patients with metastatic pancreatic cancer ...
Al-Hazzouri, Ahmed, Bendell, Johanna C, DeBusk, Laura M, Earwood, Chris, Guo, Shuangli, Ko, Andrew H, Lane, Cassie M, Murphy, Patrick B, Peyton, James D, Rodriguez, Francisco A, Shipley, Dianna L, Tempero, Margaret A, Waterhouse, David M, Womack, Mark S, Xiong, Henry Q   +14 more
core   +1 more source

Tumor Burden Score Stratifies Prognosis of Patients With Intrahepatic Cholangiocarcinoma After Hepatic Resection: A Retrospective, Multi-Institutional Study

Frontiers in Oncology, 2022
BackgroundThe prognostic significance of tumor burden score (TBS) on patients who underwent curative-intent resection of intrahepatic cholangiocarcinoma (ICC) has not been evaluated.
Hui Li, Rongqiang Liu, Haizhou Qiu, Yang Huang, Wenbin Liu, Jiaxin Li, Hong Wu, Genshu Wang, Dewei Li   +8 more
doaj   +1 more source

Elevated Preoperative Serum CA19-9 Levels in Patients with Hepatocellular Carcinoma Is Associated with Poor Prognosis after Resection

The Scientific World Journal, 2013
Serum levels of the tumor marker CA19-9 have been reported to be elevated in patients with hepatocellular carcinoma (HCC), but its clinicopathologic significance is still unknown.
Yu-Ling Chen, Chien-Hung Chen, Rey-Heng Hu, Ming-Chih Ho, Yung-Ming Jeng   +4 more
doaj   +1 more source

The Potential for Circulating Tumor Cells in Pancreatic Cancer Management. [PDF]

, 2017
Pancreatic cancer is one the most lethal malignancies. Only a small proportion of patients with this disease benefit from surgery. Chemotherapy provides only a transient benefit.
Michael Pimienta, Michael Pimienta, Mouad Edderkaoui, Ruoxiang Wang, Stephen Pandol   +4 more
core   +2 more sources

Preoperative CRP(−)/CEA(−)/CA19-9(−)/non-T4 in Stage III Colorectal Cancer Is Favorable Risk for Recurrence

Journal of the Anus, Rectum and Colon, 2022
Objectives: We evaluated the prognostic impact of a novel C-reactive protein (CRP) cut-off value (0.6 mg/dl) and carcinoembryonic antigen (CEA)/carbohydrate antigen 19-9 (CA19-9) in stage II/III colorectal cancer.
Mitsunori Ushigome, Hideaki Shimada, Tomoaki Kaneko, Yasuyuki Miura, Yasuo Nagashima, Takayuki Suzuki, Satoru Kagami, Akiharu Kurihara, Kimihiko Funahashi   +8 more
doaj   +1 more source

Cutoff value of carcinoembryonic antigen and carbohydrate antigen 19-9 elevation levels for monitoring recurrence in patients with resectable gastric adenocarcinoma

The International Journal of Biological Markers, 2009
Background The aim of this longitudinal study was to try and improve the specificity of carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 in monitoring tumor recurrence in patients with resectable gastric adenocarcinoma by setting ...
Miao-Zhen Qiu, Jun-Zhong Lin, Zhi-Qiang Wang, Feng-Hua Wang, Zhi-Zhong Pan, Hui-Yan Luo, Yu-Hong Li, Zhi-Wei Zhou, You-Jian He, Rui-Hua Xu MD, PhD   +9 more
doaj   +1 more source

Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. [PDF]

, 2013
PurposePatients with advanced cholangiocarcinoma (CC) and gallbladder carcinoma (GC) have few therapeutic options for relapsed disease. methods: Given the overall poor prognosis in this population and the availability of novel targeted therapies, we ...
Falchook, Gerald S, Fu, Siqing, Hess, Kenneth R, Hong, David S, Janku, Filip, Javle, Milind, Kaseb, Ahmed O, Kurzrock, Razelle, Naing, Aung, Piha-Paul, Sarina, Subbiah, Ishwaria M, Subbiah, Vivek, Tsimberidou, Apostolia M, Wheler, Jennifer J, Wolff, Robert A   +14 more
core   +2 more sources